{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T10:59:32Z","timestamp":1789297172586,"version":"build-2803163510"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CDC\u2019s Center for Forecasting and Outbreak Analytics","award":["CDC-RFA-FT-23-0069"],"award-info":[{"award-number":["CDC-RFA-FT-23-0069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Target trial emulation (TTE) has gained popularity in evaluating treatments and health interventions. Its application to infectious disease outcomes requires careful consideration, as infectious disease transmission violates the assumption of no interference. Thus, we conducted a scoping review to understand how TTE approaches have been applied to vaccine evaluation. We searched literature published in PubMed, Embase, and Web of Science until May 2024, using keywords related to TTE, infectious diseases, and vaccines. Full-text articles meeting inclusion criteria were further assessed for eligibility. Our keyword-based search and citation search identified a total of 241 studies. Of these, 35 original research studies used TTE approaches to evaluate vaccines, predominantly published from 2022 to 2024. The majority (n\u00a0=\u00a032, 91%) evaluated the effect of COVID-19 vaccines, with 1 study each evaluating influenza, mpox, and rotavirus vaccines. Most studies did not define which of the 4 effects of vaccination they evaluated (direct, indirect, total, or overall effect), and none incorporated interference in vaccine evaluation. Our review highlights the increasing popularity of TTE in vaccine evaluation following the COVID-19 pandemic. Further discussions are needed to establish TTE approaches to estimating 4 effects of vaccination, using large, routinely collected data.<\/jats:p>","DOI":"10.1093\/aje\/kwaf053","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:22:03Z","timestamp":1741389723000},"page":"3028-3040","source":"Crossref","is-referenced-by-count":9,"title":["Exploring the application of target trial emulation in vaccine evaluation: scoping review"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1514-3288","authenticated-orcid":false,"given":"Toshiaki","family":"Komura","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Boston University , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Boston University , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-8448","authenticated-orcid":false,"given":"Kayoko","family":"Shioda","sequence":"additional","affiliation":[{"name":"Department of Global Health, School of Public Health, Boston University , Boston, MA ,","place":["United States"]},{"name":"Center on Emerging Infectious Diseases, Boston University , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"24","key":"2025101606075353300_ref1","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA."},{"issue":"1","key":"2025101606075353300_ref2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med."},{"issue":"5","key":"2025101606075353300_ref3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.2021.2825","article-title":"Interpreting the results of intention-to-treat, per-protocol, and as-treated analyses of clinical trials","volume":"326","author":"Smith","year":"2021","journal-title":"JAMA."},{"key":"2025101606075353300_ref4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"210","author":"Deaton","year":"2018","journal-title":"Soc Sci Med."},{"issue":"3","key":"2025101606075353300_ref5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4269\/ajtmh.21-0482","article-title":"The need for a practical approach to evaluate the effectiveness of COVID-19 vaccines for low- and middle-income countries","volume":"105","author":"Nsanzimana","year":"2021","journal-title":"Am J Trop Med Hyg."},{"issue":"20","key":"2025101606075353300_ref6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med."},{"issue":"7915","key":"2025101606075353300_ref7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/d41586-022-01675-2","article-title":"Equity must be baked into randomized controlled trials","volume":"606","year":"2022","journal-title":"Nature."},{"issue":"10329","key":"2025101606075353300_ref8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(22)00176-3","article-title":"Disparity in the selection of patients in clinical trials","volume":"399","author":"Habibzadeh","year":"2022","journal-title":"Lancet."},{"issue":"8","key":"2025101606075353300_ref9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available: Table 1","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol."},{"issue":"6","key":"2025101606075353300_ref10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10654-017-0287-2","article-title":"The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening","volume":"32","author":"Garc\u00eda-Alb\u00e9niz","year":"2017","journal-title":"Eur J Epidemiol."},{"issue":"1","key":"2025101606075353300_ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/QAD.0000000000001673","article-title":"Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes","volume":"32","author":"Caniglia","year":"2018","journal-title":"AIDS."},{"key":"2025101606075353300_ref12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol."},{"key":"2025101606075353300_ref13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies","volume":"96","author":"Danaei","year":"2018","journal-title":"J Clin Epidemiol."},{"key":"2025101606075353300_ref14","author":"Hern\u00e1n","year":"2019"},{"issue":"21","key":"2025101606075353300_ref15","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget trial emulation\u201d for observational studies\u2014potential and pitfalls","volume":"391","author":"Hubbard","year":"2024","journal-title":"N Engl J Med."},{"issue":"S2","key":"2025101606075353300_ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12919-023-00285-8","article-title":"Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion","volume":"18","author":"Fernainy","year":"2024","journal-title":"BMC Proc."},{"key":"2025101606075353300_ref17","volume-title":"Planning of Experiments","author":"Cox","year":"1958"},{"issue":"371","key":"2025101606075353300_ref18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2307\/2287653","article-title":"Discussion of randomization analysis of experimental data in the Fisher randomization test","volume":"75","author":"Rubin","year":"1980","journal-title":"J Am Stat Assoc."},{"issue":"482","key":"2025101606075353300_ref19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1198\/016214508000000292","article-title":"Toward causal inference with interference","volume":"103","author":"Hudgens","year":"2008","journal-title":"J Am Stat Assoc."},{"issue":"2","key":"2025101606075353300_ref20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/00001648-199503000-00010","article-title":"Causal inference in infectious diseases","volume":"6","author":"Halloran","year":"1995","journal-title":"Epidemiology."},{"issue":"5","key":"2025101606075353300_ref21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00001648-199109000-00004","article-title":"Study designs for dependent happenings","volume":"2","author":"Halloran","year":"1991","journal-title":"Epidemiology."},{"key":"2025101606075353300_ref22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-0-387-68636-3","volume-title":"Design and Analysis of Vaccine Studies","author":"Halloran","year":"2010"},{"issue":"7","key":"2025101606075353300_ref23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"key":"2025101606075353300_ref24","doi-asserted-by":"crossref","article-title":"Exploring the application of target trial emulation in vaccine evaluation: scoping review","author":"Komura","DOI":"10.1093\/aje\/kwaf053"},{"issue":"9","key":"2025101606075353300_ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36023","article-title":"Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review","volume":"6","author":"Hansford","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"20","key":"2025101606075353300_ref26","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa2210058","article-title":"Covid-19 vaccine protection among children and adolescents in Qatar","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N Engl J Med."},{"issue":"2","key":"2025101606075353300_ref27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans","volume":"386","author":"Dickerman","year":"2022","journal-title":"N Engl J Med."},{"issue":"5","key":"2025101606075353300_ref28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/M21-4130","article-title":"The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine: a retrospective cohort study","volume":"175","author":"Gazit","year":"2022","journal-title":"Ann Intern Med."},{"issue":"1","key":"2025101606075353300_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyad138","article-title":"Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation","volume":"53","author":"Catal\u00e0","year":"2024","journal-title":"Int J Epidemiol."},{"issue":"3","key":"2025101606075353300_ref30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/M21-3256","article-title":"COVID-19 vaccination effectiveness against infection or death in a national U.S. health care system: a target trial emulation study","volume":"175","author":"Ioannou","year":"2022","journal-title":"Ann Intern Med."},{"issue":"12","key":"2025101606075353300_ref31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.7326\/M22-1856","article-title":"Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era","volume":"175","author":"Ioannou","year":"2022","journal-title":"Ann Intern Med."},{"key":"2025101606075353300_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101326","article-title":"Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: a target trial emulation study in the U.S. Veterans Affairs healthcare system","volume":"45","author":"Ioannou","year":"2022","journal-title":"EClinicalMedicine."},{"issue":"1","key":"2025101606075353300_ref33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-023-02795-w","article-title":"Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19","volume":"21","author":"Wei","year":"2023","journal-title":"BMC Med."},{"issue":"7","key":"2025101606075353300_ref34","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2666-5247(23)00103-9","article-title":"Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation","volume":"4","author":"Gazit","year":"2023","journal-title":"Lancet Microbe."},{"issue":"1","key":"2025101606075353300_ref35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41564-022-01272-z","article-title":"Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans","volume":"8","author":"Dickerman","year":"2023","journal-title":"Nat Microbiol."},{"issue":"1","key":"2025101606075353300_ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000229","article-title":"Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort","volume":"2","author":"Tran","year":"2023","journal-title":"BMJ Med."},{"issue":"39","key":"2025101606075353300_ref37","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1016\/j.vaccine.2023.07.065","article-title":"Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: a target trial emulation study","volume":"41","author":"Monteiro","year":"2023","journal-title":"Vaccine."},{"issue":"12","key":"2025101606075353300_ref38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(23)00225-0","article-title":"Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial","volume":"7","author":"Kildegaard","year":"2023","journal-title":"Lancet Child Adolesc Health."},{"issue":"1","key":"2025101606075353300_ref39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ije\/dyac199","article-title":"Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales","volume":"52","author":"Kerr","year":"2023","journal-title":"Int J Epidemiol."},{"issue":"2","key":"2025101606075353300_ref40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ije\/dyad002","article-title":"Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the virus watch community cohort","volume":"52","author":"Nguyen","year":"2023","journal-title":"Int J Epidemiol."},{"issue":"12","key":"2025101606075353300_ref41","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/cid\/ciac328","article-title":"Relative vaccine effectiveness of a severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine booster dose against the omicron variant","volume":"75","author":"Butt","year":"2022","journal-title":"Clin Infect Dis."},{"issue":"1","key":"2025101606075353300_ref42","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1038\/s41467-023-38503-8","article-title":"Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US veteran populations","volume":"14","author":"Kelly","year":"2023","journal-title":"Nat Commun."},{"issue":"12","key":"2025101606075353300_ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45417","article-title":"Infections, hospitalizations, and deaths among US nursing home residents with vs without a SARS-CoV-2 vaccine booster","volume":"5","author":"McConeghy","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025101606075353300_ref44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-075286","article-title":"Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged \u226550 years in Nordic countries: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ."},{"issue":"12","key":"2025101606075353300_ref45","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1016\/S2666-5247(22)00287-7","article-title":"Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study","volume":"3","author":"Chemaitelly","year":"2022","journal-title":"Lancet Microbe."},{"issue":"5","key":"2025101606075353300_ref46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M21-4269","article-title":"Challenges in estimating the effectiveness of COVID-19 vaccination using observational data","volume":"176","author":"Hulme","year":"2023","journal-title":"Ann Intern Med."},{"issue":"1","key":"2025101606075353300_ref47","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2665-9913(23)00272-2","article-title":"Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial","volume":"6","author":"Hanberg","year":"2024","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"2025101606075353300_ref48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/EDE.0000000000001709","article-title":"Comparison of the test-negative design and cohort design with explicit target trial emulation for evaluating COVID-19 vaccine effectiveness","volume":"35","author":"Li","year":"2024","journal-title":"Epidemiology."},{"issue":"5","key":"2025101606075353300_ref49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cmi.2023.12.010","article-title":"Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach","volume":"30","author":"Choi","year":"2024","journal-title":"Clin Microbiol Infect."},{"issue":"3","key":"2025101606075353300_ref50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/cid\/ciad604","article-title":"Early mortality after the first dose of COVID-19 vaccination: a target trial emulation","volume":"78","author":"McConeghy","year":"2024","journal-title":"Clin Infect Dis."},{"issue":"3","key":"2025101606075353300_ref51","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.vaccine.2023.12.066","article-title":"JYNNEOS\u2122 effectiveness as post-exposure prophylaxis against mpox: challenges using real-world outbreak data","volume":"42","author":"Rosen","year":"2024","journal-title":"Vaccine."},{"key":"2025101606075353300_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100755","article-title":"Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study","volume":"34","author":"Lazar, Neto","year":"2024","journal-title":"Lancet Reg Health Am."},{"issue":"1","key":"2025101606075353300_ref53","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-024-45334-8","article-title":"Comparative effectiveness of alternative intervals between first and second doses of the mRNA COVID-19 vaccines","volume":"15","author":"Shioda","year":"2024","journal-title":"Nat Commun."},{"issue":"4","key":"2025101606075353300_ref54","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/EDE.0000000000001363","article-title":"Estimating the effectiveness of rotavirus vaccine schedules","volume":"32","author":"Butler","year":"2021","journal-title":"Epidemiology."},{"issue":"15","key":"2025101606075353300_ref55","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"2025101606075353300_ref56","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med."},{"issue":"10316","key":"2025101606075353300_ref57","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet."},{"issue":"22","key":"2025101606075353300_ref58","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 vaccine against Delta variant in adolescents","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2025101606075353300_ref59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1056\/NEJMoa2205011","article-title":"BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age","volume":"387","author":"Cohen-Stavi","year":"2022","journal-title":"N Engl J Med."},{"issue":"10","key":"2025101606075353300_ref60","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41591-021-01490-8","article-title":"Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy","volume":"27","author":"Dagan","year":"2021","journal-title":"Nat Med."},{"key":"2025101606075353300_ref61","author":"The World Bank"},{"issue":"3","key":"2025101606075353300_ref62","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep."},{"issue":"9\u201312","key":"2025101606075353300_ref63","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/0270-0255(86)90088-6","article-title":"A new approach to causal inference in mortality studies with a sustained exposure period\u2014application to control of the healthy worker survivor effect","volume":"7","author":"Robins","year":"1986","journal-title":"Math Model."},{"issue":"7","key":"2025101606075353300_ref64","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.spl.2011.02.019","article-title":"Effect partitioning under interference in two-stage randomized vaccine trials","volume":"81","author":"VanderWeele","year":"2011","journal-title":"Stat Probab Lett."},{"issue":"2","key":"2025101606075353300_ref65","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/sim.7392","article-title":"Estimating population effects of vaccination using large, routinely collected data","volume":"37","author":"Halloran","year":"2018","journal-title":"Stat Med."},{"issue":"3","key":"2025101606075353300_ref66","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/biom.12184","article-title":"Assessing effects of cholera vaccination in the presence of interference","volume":"70","author":"Perez-Heydrich","year":"2014","journal-title":"Biometrics."},{"issue":"2","key":"2025101606075353300_ref67","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/biom.13459","article-title":"Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring","volume":"78","author":"Chakladar","year":"2022","journal-title":"Biometrics."},{"issue":"8","key":"2025101606075353300_ref68","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/aje\/kwab040","article-title":"Emulating target trials to improve causal inference from agent-based models","volume":"190","author":"Murray","year":"2021","journal-title":"Am J Epidemiol."},{"issue":"5","key":"2025101606075353300_ref69","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/aje\/kwaa239","article-title":"Disseminated effects in agent-based models: a potential outcomes framework and application to inform preexposure prophylaxis coverage levels for HIV prevention","volume":"190","author":"Buchanan","year":"2021","journal-title":"Am J Epidemiol."},{"issue":"3","key":"2025101606075353300_ref70","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/add.14797","article-title":"Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis","volume":"115","author":"Morozova","year":"2020","journal-title":"Addiction."},{"issue":"4","key":"2025101606075353300_ref71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4602","article-title":"Depression onset after a spouse\u2019s cardiovascular event","volume":"7","author":"Komura","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"1","key":"2025101606075353300_ref72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-publhealth-040617-014317","article-title":"Agent-based modeling in public health: current applications and future directions","volume":"39","author":"Tracy","year":"2018","journal-title":"Annu Rev Public Health."},{"issue":"5","key":"2025101606075353300_ref73","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/aje\/kwy262","article-title":"Systems modeling to advance the promise of data science in epidemiology","volume":"188","author":"Cerd\u00e1","year":"2019","journal-title":"Am J Epidemiol."},{"issue":"8","key":"2025101606075353300_ref74","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jand.2020.02.013","article-title":"The special supplemental nutrition program for women, infants, and children spillover effect: do siblings reap the benefits?","volume":"120","author":"Steeves","year":"2020","journal-title":"J Acad Nutr Diet."},{"issue":"18","key":"2025101606075353300_ref75","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1002\/sim.9427","article-title":"Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data","volume":"41","author":"Buchanan","year":"2022","journal-title":"Stat Med."},{"key":"2025101606075353300_ref76","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071349","article-title":"Bias by censoring for competing events in survival analysis","volume":"378","author":"Coemans","year":"2022","journal-title":"BMJ."},{"issue":"1","key":"2025101606075353300_ref77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/2632084320961043","article-title":"Causal survival analysis: a guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence","volume":"2","author":"Murray","year":"2021","journal-title":"Res Methods Med Health Sci."},{"issue":"1","key":"2025101606075353300_ref78","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaf053\/62382304\/kwaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/10\/3028\/62382304\/kwaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/10\/3028\/62382304\/kwaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:07:57Z","timestamp":1760609277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/10\/3028\/8071274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":78,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,3,10]]},"published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaf053","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.26.24311066","asserted-by":"object"}]},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,3,10]]}}}